https://www.researchgate.net/profile...l-evidence.pdf
So this is an Australian study (a systematic review) published in the Journal of Neurology, Neurosurgery and Psychiatry (a BMJ [British Medical Journal] journal) reviewing the use of cannabis as an adjunct (add on) therapy for treatment resistant epilepsy. It’s pretty positive and emphasises the need for further studies.
Conclusions*
Few high-quality RCTs have been conducted to date, and those that currently exist have tested CBD in paediatric samples with rare and serious forms of drug-resistant epilepsy. Of these existing studies, a reasonable proportion of patients experienced a decrease in seizure frequency when using pharmaceutical grade CBD products in addition to AEDs; however, minor AEs (adverse events) were likely and complete seizure freedom was unlikely. The timely completion and publication of RCTs will provide a better basis for assessing the benefits and risks of cannabinoid products to control epilepsy. These results will also provide a better basis for a more rational and informed clinical use of cannabis-based products and cannabinoids to treat drug-resistant epilepsy.
Bookmarks